About
The
Company
Asep Inc. consolidates three development-stage companies —
Sepset Bioscience, ABT Innovations and SafeCoat Medical
all with shared missions, founders and investors.
Our purpose is to mitigate the global crisis of antibiotic failure by improving patients’ odds of survival and quality of life.
Together, our diagnostic and therapeutic solutions represent tremendous clinical and commercial potential, through rapid diagnostics and uniquely effective treatments.
Diagnostic
Offering:
Novel diagnostic assay for the early and rapid risk assessment of sepsis.
Impact:
Dramatically faster test results, for a health crisis where every hour counts.
Therapeutic
Offering:
Patented peptide technology targets infection-causing biofilms and reduces inflammation.
Impact:
Effectively treats antibiotic-resistant infections, where nothing else works.
Offering:
Substrate-independent, antibacterial peptide coatings.
IMPACT:
Vastly improved sterile surfaces for medical instruments and implants.
Our Values
To continually innovate to address the global crisis of antibiotic failure, improving survivability and quality of life for patients.
Mission
To combine the best scientific, development and business teams to provide the best possible care to those suffering with antibiotic-resistant infections.
Our Vision
To become the global market leader in the diagnosis and treatment of antibiotic-resistant infections.
Leadership
Dr. Robert Hancock
Founder, Chairman & Chief Executive Officer
Dr. Hancock is a leading microbiologist in Canada who has researched and taught at the University of British Columbia for nearly 40 years. His chief interest is in designing new therapeutic strategies to treat infections and inflammation in the light of increasing antibiotic resistance, coupled with a dearth of new antibiotic discovery. His research interests include cationic host defense peptides as novel antimicrobials, anti-biofilm agents, anti-inflammatory agents and modulators of innate immunity. He has published more than 760 papers and reviews, has more than 100,000 citations, an h-index of 162, and 65 patents awarded. Awards and honors include the Prix Galien (Highest award for Canadian Pharmaceutical Research and Innovation), the Killam Prize (Canada Council’s prize for Health Research), Michael Smith CIHR Researcher of the Year, and the ICAAC Aventis Antimicrobial Research Award (Leading award worldwide for antimicrobial research). In 2001 he was inducted as an Officer of the Order of Canada.
Tim Murphy
CHIEF OPERATIONS OFFICER
Tim is an experienced business executive and international lawyer. He sits on numerous company boards and is the Founding Partner of Murphy & Company LLP, a leading business law firm in Vancouver, Canada. Prior to founding Murphy & Company, he practised law with a prominent national law firm in Calgary, Alberta, gained international experience as an associate in the finance law group of a British “magic circle” law firm and served as in-house legal counsel for a multinational software company in Paris, France. Tim holds a bachelor of laws (LL.B) degree from the University of Saskatchewan, a master of laws (LL.M) degree from McGill University and is a member of the law societies of British Columbia and England & Wales.
Dr. Evan Haney
Chief SCIENTIFIC Officer
Dr. Haney is an experienced scientist and research coordinator, who has managed a team of up to 20 individuals over the past 10 years. He is an inventor on the peptide patents that are core to ASEP’s therapeutic technology and has in-depth experience with the various endeavors relevant to clinical research. He has published over 40 papers in scientific journals related to peptide optimization and their development as therapeutics. Dr. Haney holds a Ph.D. in Biochemistry from the University of Calgary.
Dr. Fadia Saad
Chief Business Development Officer
Dr. Saad has an extensive track record in strategic planning and implementation of significant projects for global companies. As Head of Business Development at Aspreva Pharmaceuticals, she produced licensing strategies and led teams in the analysis of licensing opportunities. She oversaw and directed all Business Development projects and assigned resources within established budget requirements, as well as managing operations of teams in R&D, intellectual property, finance and product commercialization.
Dr. Saad has led more than 15 on-site due diligences and played an integral role in negotiating a number of M&As of a cumulative value exceeding $2 Billion. She has a PhD in Microbiology from McGill University and an MBA from HEC (Hautes Etudes Commerciales), University of Montreal.
Dr. Rob Stenstrom
Medical Director
Dr. Stenstrom completed his medical training at McMaster University and his Family & Emergency Medicine residency at the University of Ottawa. He also holds a Ph.D. in Epidemiology and Biostatistics from McGill University. His research interests include sepsis, septic shock, emergency medicine, resistant bacteria, skin and soft tissue infections, and infectious diseases in the emergency department. He has also been involved in developing guidelines for managing and treating severe sepsis in the emergency department. He is a Canadian Association of Emergency Physicians Critical Care Committee member. Since 2003, Dr. Stenstrom has been an emergency department physician at St. Paul’s Hospital. He also held the role of Research Director at St. Paul’s Hospital Department of Emergency Medicine from 2005 – 2018. In addition to his work at St. Paul’s Hospital, he has been active in the Faculty of Medicine at the University of British Columbia (UBC) since 2003. He currently holds the title of Clinical Professor of Medicine within the Department of Emergency Medicine at UBC.
Jacqueline M. Tucker
Chief Financial Officer
Ms. Tucker is the president of J.M. Tucker Professional Corp. The company was established in 1995 in Vancouver, BC, providing audit and related financial services to emerging companies in the resource, bio-medical and high-tech industries. In 2005, Ms. Tucker relocated to Calgary, Alberta, and realigned the company’s areas of practice to include contract Chief Financial Officer services and advisory services to Canadian public companies including financial reporting, disclosure issues, and compliance with securities legislation. During her career, Ms. Tucker has held a number of senior executive officer positions including CEO and CFO with Canadian public companies as well as holding various board positions.
Board of Directors
Dr. Robert Hancock
Chairman
Dr. Hancock is a leading microbiologist in Canada who has researched and taught at the University of British Columbia for nearly 40 years. His chief interest is in designing new therapeutic strategies to treat infections and inflammation in the light of increasing antibiotic resistance, coupled with a dearth of new antibiotic discovery.
Derrold Norgaard
DIRECTOR, CHAIR – AUDIT COMMITTEE
Derrold Norgaard is a Fellow of the Chartered Professional Accountants of British Columbia. He held the dual role of Tax Partner and Office Managing Partner at KPMG until 2008. Norgaard’s primary areas of practice include personal tax planning, international tax and corporate taxation. He has authored several articles on Canadian tax planning and has been an instructor in Canadian tax programs for many years. He is a frequent speaker to business groups throughout Canada and Asia.
Tim Murphy
Director
Tim Murphy is an experienced business executive and international lawyer. He is the Founding Partner of Murphy & Company, LLP, a leading business law firm in Vancouver, Canada, and has over 15 years of experience advising high growth companies on mergers and acquisitions, technology and finance matters. Mr. Murphy has executive experience as a CEO and has served on the boards of numerous public and private companies.
Dr. Richard Heinzl
Director
Dr. Heinzl is a physician, humanitarian, entrepreneur and author whose current focus is genomics, artificial intelligence and healthcare worldwide. Based in New York and Toronto, he is currently CEO of My Next Health Inc.
Advisory Board
General Wesley K. Clark, (U.S. Army ret.)
General Wesley Clark is a businessman, educator, writer and commentator (most notably with CNN). He is also a retired U.S. Army officer, serving as the Supreme Allied Commander, Europe of NATO, from 1997 to 2000. He graduated as valedictorian of the class of 1966 at West Point and was awarded a Rhodes Scholarship to the University of Oxford. He spent 38 years in the U.S. Army, receiving many military decorations, honorary knighthoods and the Presidential Medal of Freedom.
Mr. David Johnson
David Johnson is the CFO and a director of TLG Acquisition One Corp., a Florida-based strategic business consultancy with expertise in mergers, capital stock exchange, asset acquisition, stock purchase and reorganization. Mr. Johnson has decades of experience with multinational organizations and has specific expertise in mergers and acquisitions and related acquisition integration. He has previously served as a senior managing director responsible for technology investments at Blackstone Group, a leading investment firm.
Mr. Patrick McBride
Patrick McBride brings more than 15 years of experience in the financial industry and has held several senior roles at investment banks including Genuity, Canaccord Genuity and Dundee Capital and Eight Capital. He has raised in excess of CAD $10 billion of growth capital for companies across relevant sectors including biotech, technology and commodities. In addition, Mr. McBride has an extensive M&A track record totalling over CAD $3 billion. Mr. McBride is also a CFA Charterholder.
Dr. Islam Mohamed, BSc MD FRCPC
Dr. Mohamed is an experienced Radiation Oncologist who began his practice at the BC Cancer Agency in 2000. He completed a Bachelor’s degree in Genetics before entering medicine at the University of Alberta. After his residency in Radiation Oncology at Edmonton’s Cross Cancer Institute, he joined BC Cancer, Kelowna and where he specialized in breast, lung, and sarcoma tumour sites. His current practice includes lung, sarcoma and skin tumour sites, with a particular interest in stereotactic radiosurgery.
Dr. Christopher S. Mow, MD
Dr. Mow currently serves as the Associate Chief of Staff and Clinical Professor of Orthopaedic Surgery at Stanford University Medical Center. With over 25 years of experience in international collaboration, research, training, infrastructure development and healthcare policy, finance and management throughout the Asia Pacific region, including and especially China, Prof. Mow is considered to be a global healthcare leader by patients, public officials, academic medicine, the financial sector and industry alike.
Mr. Thomas O’Shaughnessy
Thomas O’Shaughnessy is a seasoned business executive with over twenty-one years of strategy and operations experience with a core focus on health care. His expertise includes strategic planning, system design, project implementation, and senior-level stakeholder engagement. Mr. O’Shaughnessy is the President of Healthtech – a Nordic Global Company.
collaborators/partners
GenomeCanada
iFyber
IQVIA
NMIN
Vetoquinol
We’ve got big plans
Stay in the loop
ASEP and its subsidiaries' technologies have not received marketing authorization
and are not currently available for purchase. © 2023 All Rights Reserved